Aptuit Names Henning Steinhagen as EVP Drug Discovery and Development, and Site-Head Verona

USA - English

• USA - Français
• USA - español
• USA - Deutsch

GREENWICH, Connecticut, June 1, 2016 /PRNewswire/ --

Jonathan Goldman, CEO of Aptuit LLC, announced today the appointment of Henning Steinhagen, PhD, as Executive Vice President Drug Discovery and Development, and Site-Head Verona, completing Aptuit's executive leadership team.

     (Logo: http://photos.prnewswire.com/prnh/20150709/234432LOGO )

Dr. Steinhagen will focus on the growth of Aptuit as a leading partner research organization and provider of outsourced services in the early discovery and development space. He joins Aptuit from Grünenthal, a global pharmaceutical company. He stated, "I am delighted to be joining Aptuit Verona and becoming part of this incredibly talented team. Verona's strong track record and legacy of being the world's premier integrated Research and Development partner research organization is well deserved. Verona is poised for continued growth and success; I look forward to helping our valued customers achieve successful outcomes through the quality and speed of our integrated research and development capabilities."

At Grünenthal, Dr. Steinhagen was Senior Vice President, and Head of Global Drug Discovery. His accomplishments included discovery successes in multiple therapeutic areas and establishing multiple research partnerships. Before joining Grünenthal, Dr. Steinhagen served for 7 years at Sanofi-Aventis in positions of increasing responsibility in medicinal chemistry. Before that he was in the medicinal chemistry group at Bayer.

Dr. Steinhagen holds a PhD from the University of Heidelberg, Germany, in Organic Chemistry as well as a minor degree in Molecular Genetics. His experience also includes several years as a post-doctoral fellowship at Harvard University, USA, and senior academic appointments at RWTH University Aachen, Germany, and Trinity College Dublin, Ireland.

Dr. Goldman commented, "I am delighted that Henning is joining us. He brings exceptional experience in science, leadership and partnerships that are needed to advance our growth. His collaborative approach to understanding and delivering unmet needs of our customers makes him ideally suited to lead the Verona senior management team."

Dr. Goldman, added, "Aptuit is the only organization able to deliver fully integrated discovery as well as GMP (API and drug product) and GLP development literally under one roof. We have shown unparalleled success in candidate nomination and IND program completion in multiple therapeutic areas. Henning is a unique individual with the perfect skill set to take us to the next level."

Aptuit, LLC provides the most complete set of integrated early discovery to mid-phase drug development services in the pharmaceutical industry including Drug Design & Discovery, API Development and Manufacture, Solid State Chemistry, CMC, Preclinical and IND enabling GLP/GMP programs. Fully integrated drug discovery & development services are available from our facilities in the UK, Italy, and Switzerland. Aptuit, LLC is partnered with Welsh, Carson, and Anderson & Stowe, one of the world's leading private equity investors.  

For more information, please visit http://www.aptuit.com

SOURCE Aptuit, LLC